1-3 of 3
John Sanil Manavalan
Close
Sort by
Journal Articles

Pembrolizumab in Combination with Epigenetic Therapy Is Safe and Active in Heavily Treated Patients with Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-Cell Lymphoma (CTCL): Preliminary Results from the Embolden Trial

Nathan Roberts, John Lister, N. Nora Bennani, Salvia Jain, Tammy Battaglia, Emily C. Ayers, Craig A. Portell, Michael E. Williams, Prem Batchala, Ipsita Pal, Owen A. O'Connor, John Sanil Manavalan, Enrica Marchi
Journal: Blood
Blood (2022) 140 (Supplement 1): 9425–9426.
https://doi.org/10.1182/blood-2022-170181
Published: 2022
Journal Articles

Tolinapant, a Non-Peptidomimetic Antagonist of Inhibitors of Apoptosis Proteins, cIAP1/2 and XIAP, in Combination with the Hypomethylating Agents, Azacytidine and Decitabine Are Highly Synergistic in in Vitro Models of T Cell Lymphoma

John Sanil Manavalan, Ipsita Pal, Aidan Pursley, George A. Ward, Tomoko Smyth, Martin Sims, Jason A. Taylor, David J Feith, Thomas P. Loughran, Jr., Owen A. O'Connor, Enrica Marchi
Journal: Blood
Blood (2022) 140 (Supplement 1): 11552–11553.
https://doi.org/10.1182/blood-2022-169906
Published: 2022
Journal Articles

The Novel Nano-Formulation of the HDAC Inhibitor, Romidepsin, for the Treatment of Relapsed, Refractory Peripheral T-Cell Lymphoma

Ipsita Pal, Anuradha Illendula, John Sanil Manavalan, Todd P Fox, Owen A. O'Connor, Thomas P. Loughran, Jr., Mark Kester, David J Feith, Enrica Marchi
Journal: Blood
Blood (2022) 140 (Supplement 1): 8848–8849.
https://doi.org/10.1182/blood-2022-167628
Published: 2022